



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Patrizio Mattei, et. al.

Group:

Serial No. 10/613,782, filed July 3, 2003

Examiner:

Docket No. 21159

For:

QUINAZOLINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 September 26, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A7, and B1-B11 listed on Form PTO-1449 are enclosed.

Documents B4, B5 and B6, which are not written in the English language, correspond to Documents A3, A4, and A5, respectively.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/613,782

Filed: July 3, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully Submitted,

Attorney for Applicant

Eileen M. Ebel (Reg. No. 37,316)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-4391

Telefax: (973) 235-4391

134562

PTO/SB/21 (01-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/613,782 TRANSMITTAL Filing Date July 3, 2003 **FORM** First Named Inventor Mattei Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number 21159 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to Group Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to Group Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Identify below): Extension of Time Request Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Form 1449 with references Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Eileen M. Ebel

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date September 26, 2003 Typed or printed Eileep M. Ebel Signature Date September 26, 2003

Individual Signature Date

September 26, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

134	Substitute for form 1449A/PTO				Complete if Known			
3 E INE	E INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 10/613,782			
					Filing Date	July 3, 2		
				Ī	First Name Inventor	Mattei		
(Use several sheets if necessary)					Group Art Unit			
					Examiner Name		15.	
Sheet 1		of	1		Attorney Docket Number	21159		
				U.S. PAT	ENT DOCUMENTS			
		U.S. Patent Documer		nent	None of Detentes on Anni	:t of	Date of Publication of	
Examiner Initials'	Cite No.¹	Number		Kind Code ²	Name of Patentee or Applicant of Cited Document		Cited document	
				(if known)	Chou Boodinent		MM-DD-YYYY	
	A1	4,598,089			Hadvary, et. al.		07/01/1986	
	A2	6,004,996			Shah, et. al.		12/21/1999	
	A3	4,931,463			Barbier, et. al.		06/05/1990	
	A4	4,983,746		1	Barbier, et. al.		01/08/1991	
	A5	5,399,720			Karpf, et. al.		03/21/1995	
	A6	4,035,367			Simpson, William R.		07/12/1977	
	A7	6,573,263		<u> </u>	Niewohner, et. al.		06/2003	
	A/	0,37	3,203		Mewornier, et. ar.		00/2003	
	L		FO	DEICN D	ATENT DOCUMENTS		1	
-		Foreig	gn Patent Docum		ATENT DOCUMENTS	Da	te of Publication of T	
Examiner	Cite	Office ³ Number ⁴ Kind Coo (if known)			Name of Patentee or		Cited Document	
Initials'	No.1				Applicant of Cited Docum	ent 1	MM-DD-YYYY	
	B1	WO 99/34786			Geltex Pharmaceuticals, Inc.		/15/1999	
	B2	WO 00/09122			F. Hoffmann-La	02.	/24/2000	
•					Roche AG			
	В3	WO 00/09123			F. Hoffmann-La 02. Roche AG		/24/2000	
	B4	EP 0 185 359					06/25/1986	
	B5	EP 0 189 577 EP 0 443 449		<u> </u>			08/06/1986	
	D3							
	B6						/28/1991	
	טע				& Co.		00,20,1771	
	B7	EP 0 524 495					01/27/1993	
	ש'	EF U 324 473			Roche & Co.		. =	
	B8	WO 02 20499					/14/2002	
	DØ	WO 02 20488			Roche AG		117/2002	
	DO	11/0 02 004700					/28/2002	
	B9	WO 02 094789			F. Hoffmann-La 11/28/2002		12012002	
	<u> </u>	D10 WO 06 27474			Roche AG		/29/1006	
ı	B10	B10 WO 96 3747			Warner-Lambert	11	/28/1996	
	<u> </u>				Company		10.5/20.04	

Examiner	Date Considered	
Signature		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

Neurogen Corporation

04/05/2001

WO 01 23389

B11

^{*}EXAMINER: Initial in reference considered, whether of not citation is in contomance with for Examiner. So and the contomance and the contomance with the citation is in contomance with form with next communication to applicant.

*Unique citation designation number. See attached Kinds of U.S. Patent Documents. The patent document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation or abstract is attached.